F1Q strength is not the pace embedded for the rest of FY27
Year-over-year adjusted segment operating-profit growth: F1Q27 actual versus approximate combined F2Q27–F4Q27 growth implied by FY27 guidance
Connected dot plot comparing Q1 FY27 adjusted segment profit growth with approximate growth implied for Q2-Q4. North American Pharmaceutical slows from 19.4% to 6.8% and Oncology from 41.1% to 9.1%; RxTS remains near 13%, while Medical-Surgical must rebound from a 20.1% decline to 8.9% growth.
